dNovo Bio
dNovo Bio is a preclinical biotechnology company developing direct reprogramming technology to convert a patient's own skin, blood, or fat cells into autologous hair stem cells and dermal papilla cells for permanent treatment of male pattern baldness and age-associated hair loss.
- Company typePrivate
- Founded2018
- HeadquartersSan Jose, United States
- Headcount1–10
- GTM typeB2C
- OfferingServices
dNovo Bio firmographics
Firmographics- Name
- dNovo Bio
- Legal name
- dNovo
- Website
- https://dnovobio.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- dNovo Bio is a preclinical biotechnology company developing direct reprogramming technology to convert a patient's own skin, blood, or fat cells into autologous hair stem cells and dermal papilla cells for permanent treatment of male pattern baldness and age-associated hair loss.
- Ownership category
- akta.pro rank
dNovo Bio industry classification
Industry- Product category
- Regenerative Medicine
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Cell Therapy Developers (Autologous) (HLAAABAA)
Keywords
Where dNovo Bio is headquartered
LocationHeadquarters
- HQ city
- San Jose
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
dNovo Bio business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Hair Stem Cell Treatment: Pre-revenue biotech company developing a permanent hair loss cure through personalized hair stem cell generation. Revenue model will likely involve medical treatment/procedure fees for cell collection, reprogramming, and transplantation.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
dNovo Bio product offering
Product offeringCore offering
dNovo Bio develops a proprietary direct reprogramming technology that converts a patient's own cells (skin, blood, or fat) into personalized hair stem cells and dermal papilla cells to permanently treat hair loss caused by DHT-induced male patterned baldness and age-associated hair miniaturization. The planned treatment is administered at the company's onsite facility through a five-step process involving cell collection, application of proprietary reprogramming factors, generation of hair-producing cells, and seeding onto the scalp, with hair growth expected within 1-3 months. The company is pre-commercial and operates in stealth-mode development with animal-model validation.
Product overview
dNovo Bio is a biotech company offering a single unified therapeutic approach centered on its proprietary direct reprogramming technology. The core offering converts a patient's own cells (from skin, blood, or fat) into personalized hair stem cells and dermal papilla cells, which are then transplanted to treat hair loss at its root cause. The five-step process involves cell collection, application of proprietary reprogramming factors, generation of hair-producing cells, seeding onto the scalp, with visible hair growth expected in 1-3 months. The company operates from its Silicon Valley facility and focuses exclusively on permanent hair loss treatment through stem cell regeneration rather than temporary solutions.
Differentiator
Problem solved
Functional benefit
Products and services
- Personalized Hair Stem Cell Therapy Pre-commercial planned medical service that addresses the root cause of hair loss (hair stem cell loss) by collecting a small skin sample or a few drops of blood from the patient, applying proprietary direct reprogramming factors to generate personalized hair stem cells and dermal papilla cells, and transplanting them onto the scalp. Designed for individuals with DHT-induced male patterned baldness and age-associated hair miniaturization, offering a permanent regenerative solution compatible with the patient's immune system.
Quantifiable outcome
- Hair growth visible in 1-3 months after treatment
- +1 more outcomes
Companies that use dNovo Bio
Customer profileSegments2 records
Ideal customer profiles1 record
dNovo Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
dNovo Bio partnerships and signals
Strategic signalScale indicators5 records
Recent moves6 records
Expansion highlights4 records
dNovo Bio competitors and assessment
Company assessmentDirect peers
- Stemson Therapeutics: Stemson is developing iPSC-derived hair follicle cells to treat hair loss, the most direct competitor to dNovo in cellular hair regeneration; both pursue patient-derived reprogrammed cells rather than transplants or topicals.
- RepliCel Life Sciences: RepliCel is developing autologous cell therapies (RCH-01 dermal sheath cup cells) for hair loss, making it a direct comparator in the autologous hair cell therapy space alongside dNovo.
- Histogen: Histogen is developing regenerative treatments for hair loss using proprietary cell-conditioned media and HSC-derived stimulators, targeting the same hair loss indication via cell-based approaches.
- Turn Biotechnologies: Turn Bio develops mRNA-based direct reprogramming (epigenetic reprogramming) to restore youthful cell function across multiple tissues, sharing dNovo's core scientific premise of direct cellular reprogramming for age-related conditions.
Emerging players
- AgeX Therapeutics: AgeX is a clinical-stage company focused on cellular rejuvenation and induced tissue regeneration (iTR) technology, targeting age-related degenerative conditions with a related but broader platform than dNovo's hair focus.
Broad incumbents
- Biosplice (formerly Samumed): Biosplice is a well-funded late-stage biotech developing Wnt-pathway small molecules (lorecivivint and hair loss candidate) that represent a competing mechanism-of-action for hair regeneration versus dNovo's cell therapy approach.
- Aderans Company: Aderans is a global hair restoration incumbent (wig/hairpiece plus cell-based R&D via subsidiary) pursuing hair regeneration through autologous cell technologies and tissue engineering, comparable as a broader incumbent in the hair regeneration space.
- Shiseido: Shiseido operates a hair science research program (Replicel partnership history, hair growth factor research) within its broader beauty R&D, making it a large incumbent researching regenerative hair solutions with relevant scientific overlap.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
dNovo Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
dNovo Bio leadership team
Management profileNumber of profiles
Profiles1 record
dNovo Bio funding detail
Funding detailFunding overview
Funding rounds2 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
dNovo Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about dNovo Bio
What does dNovo Bio do?
dNovo Bio develops a proprietary direct reprogramming technology that converts a patient's own cells (skin, blood, or fat) into personalized hair stem cells and dermal papilla cells to permanently treat hair loss caused by DHT-induced male patterned baldness and age-associated hair miniaturization. The planned treatment is administered at the company's onsite facility through a five-step process involving cell collection, application of proprietary reprogramming factors, generation of hair-producing cells, and seeding onto the scalp, with hair growth expected within 1-3 months. The company is pre-commercial and operates in stealth-mode development with animal-model validation.
Is dNovo Bio a public or private company?
dNovo Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was dNovo Bio founded?
dNovo Bio was founded in 2018. It employs 1 to 10 people.
Where is dNovo Bio based?
dNovo Bio is headquartered in San Jose, United States, in the North America region.
How does dNovo Bio make money?
One revenue line is on record: hair Stem Cell Treatment.
Who are dNovo Bio's main competitors?
Direct peers on record are Stemson Therapeutics, RepliCel Life Sciences, Histogen and Turn Biotechnologies. AgeX Therapeutics is listed as an emerging player. Broad incumbents are Biosplice (formerly Samumed), Aderans Company and Shiseido.
Does dNovo Bio have an API?
No public API is recorded for dNovo Bio.
What industry is dNovo Bio in?
dNovo Bio's product category is Regenerative Medicine. Its primary akta.pro industry code is HLAAABAA, Cell Therapy Developers (Autologous). Its NAICS code is 541714 and its SIC code is 2836.